The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis

Precision medicine approaches based on genomic abnormalities have brought a paradigm shift in the treatment for patients with advanced non-small cell lung cancer (NSCLC) in the past decades. [1] Anaplastic lymphoma kinase (ALK) inhibitors for oncogenic ALK gene rearranged NSCLC, noted in 3.6 to 4.4% of patients with NSCLC, [2,3] is one of the leading examples of precision oncology for lung cancer. In 2011, crizotinib received accelerated approval for the ALK-positive locally advanced or metastatic NSCLC by U.S.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research